An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma

Zhongshan ZHU; Zhou YANG; Chengchuan JIANG; Xiaobing LI; Dou REN; Cheng HUANG; Weiwei ZHANG; Xiangjun LI; Shunli ZHAO

doi:10.12259/j.issn.2095-610X.S20220912

Volume 43 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(9): 70-76

Zhongshan ZHU, Zhou YANG, Chengchuan JIANG, Xiaobing LI, Dou REN, Cheng HUANG, Weiwei ZHANG, Xiangjun LI, Shunli ZHAO. An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma[J]. Journal of Kunming Medical University, 2022, 43(9): 70-76. doi: 10.12259/j.issn.2095-610X.S20220912

Citation:

Zhongshan ZHU, Zhou YANG, Chengchuan JIANG, Xiaobing LI, Dou REN, Cheng HUANG, Weiwei ZHANG, Xiangjun LI, Shunli ZHAO. An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma[J]. Journal of Kunming Medical University, 2022, 43(9): 70-76. doi: 10.12259/j.issn.2095-610X.S20220912

Citation:

Zhongshan ZHU, Zhou YANG, Chengchuan JIANG, Xiaobing LI, Dou REN, Cheng HUANG, Weiwei ZHANG, Xiangjun LI, Shunli ZHAO. An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma[J]. Journal of Kunming Medical University, 2022, 43(9): 70-76. doi: 10.12259/j.issn.2095-610X.S20220912

PDF( 1312 KB)

An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma

doi: 10.12259/j.issn.2095-610X.S20220912

Dept. of Oncology，The 2nd People’s Hospital of Hunan，Changsha Hunan 410007，China

Received Date: 2022-06-20
Available Online: 2022-09-08
Publish Date: 2022-09-29

Abstract

Abstract

Objective To analyze PLA2G1B gene expression, prognosis, immunologic features and potential therapeutic effects in patients with lung adenocarcinoma, based on the data-mining of public databases. Methods Data from TCGA and GEO database of LUAD were collected, including gene expression matrix and clinical data. The overall survival （OS） rate was compared between these two groups of PLA2G1B high expressed and low expressed. CIBERSORT algorithm was introduced to calculate totally 22 immune cells infiltration level and their difference was also compared between PLA2G1B high and low groups. Finally, pRRophetic was used to find some drugs that were probably sensitive to the worse OS groups. Results PLA2G1B was down regulated in LUAD samples and the lower expression of PLA2G1B led to a worse OS in LUAD, this result was validated in two independent GEO cohorts. After adjusting three main clinical elements, PLA2G1B was proved to be an independent prognosis biomarker （P < 0.05）. For the worse OS group, we also found its immune infiltration level was lower than the better OS group, especially for B cell memory, T cell CD4+ memory resting, Monocyte, Myeloid dendritic cell and Mast activated cells. For the worse OS group, we found they might be more sensitive to several chemo drugs including Cisplatin, Docetaxel, Etoposide, Gemcitabine, Paclitaxeland Vinorelbine. Conclusion PLAG21B is an independent prognosis biomarker in LUAD and the ones low expressed showed worse OS and lower immune infiltration level.
- Lung adenocarcinoma,
- PLA2G1B,
- Prognosis,
- Data mining,
- Immune infiltration

FullText(HTML)

References(14)

References

[1]	Siegel,R L,K. D. Miller,A. Jemal. Cancer statistics 2020[J]. CA Cancer J Clin,2020,70(1):7-30. doi: 10.3322/caac.21590
[2]	Sung H,Ferlay J,Siegel R L,et al. Global cancer stastistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
[3]	Little A G,Gay E G,Gaspar L E,et al. National survey of non-small cell lung cancer in the United States:Epidemiology,pathology and patterns of care[J]. Lung Cancer,2007,57(3):253-260. doi: 10.1016/j.lungcan.2007.03.012
[4]	Kleczko E K,Kwak J W,Schenk E L,et al. Targeting the complement pathway as a therapeutic strategy in lung cancer[J]. Front Immunol,2019,10(10):954.
[5]	Herbst R S,Soria J C,Kowanetz M,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature,2014,515(7528):563-567. doi: 10.1038/nature14011
[6]	Shukuya T,Carbone D P. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer[J]. J Thorac Oncol,2016,11(7):976-988. doi: 10.1016/j.jtho.2016.02.015
[7]	Rizvi N A,Hellmann M D,Snyder A,et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science,2015,348(6230):124-128. doi: 10.1126/science.aaa1348
[8]	Kanda A,Tamaki M,Nakamura E,et al. Characterization of recombinant human and rat pancreatic phospholipases A2 secreted from saccharomyces cerevisiae:Difference in proteolytic processing[J]. Biochim Biophys Acta,1992,1171(1):1-10. doi: 10.1016/0167-4781(92)90133-K
[9]	Hu B,Yang X B,Sang X T. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma[J]. Cancer Medicine,2020,9(20):7646-7662. doi: 10.1002/cam4.3353
[10]	Matsuyama Y,Suzuki M,Arima C,et al. Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas[J]. Mol Carcinog.,2011,50(4):301-309. doi: 10.1002/mc.20632
[11]	Schabath M B,Welsh E A,Fulp W J,et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression,proliferation and immune surveillance in lung adenocarcinoma[J]. Oncogene,2016,35(24):3209-3216. doi: 10.1038/onc.2015.375
[12]	Chen B,Khodadoust M S,Liu CL,et al. Profiling tumor infiltrating immune cells with CIBERSORT[J]. Methods Mol Biol,2018,17(11):243-259.
[13]	Geeleher P,Cox N,Huang R S. pRRophetic:An R package for prediction of clinical chemotherapeutic response from tumor gene expression levels[J]. PloS One,2014,9(9):e107468. doi: 10.1371/journal.pone.0107468
[14]	Selvanesan B C,Chandra D,Quispe-Tintaya W,et al. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice[J]. Sci Transl Med,2022,14(637):1600. doi: 10.1126/scitranslmed.abc1600

Relative Articles(20)

Relative Articles

[1]	Xinyi MEN, Jing ZHAO, Yongchun SHEN, Hui JI, Xiuxia WANG. The Relationship between Peripheral Blood Immunoglobulin，Erythrocyte Sedimentation Rate，Homocysteine and the Degree of Central Nervous System Vasculitis in Children and Their Influence on Prognosis. Journal of Kunming Medical University, 2024, 45(12): 1-7.
[2]	Man YANG, Xingan ZHAO, Yunna GE, Juan QIN, Xiya WANG, Siming TAO. Identification of Atrial Fibrillation-related Inflammatory Genes and Their Association with Immune Cell Infiltration Based on Comprehensive Bioinformatic Analysis. Journal of Kunming Medical University, 2024, 45(3): 18-29. doi: 10.12259/j.issn.2095-610X.S20240303
[3]	Wangxun SHEN, Yinyu YANG, Canwei LI, Jinrong YANG, Sijing WU, Huajun ZHAO, Xiaoyu TUO. Expression and Clinical Significance of ROR1 in Different Histologic Types of Invasive Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20240509
[4]	Hongxiu YANG, Zhongshan ZHU. Effect of HPRT1 Gene Expression on Overall Survival of Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(8): 17-23. doi: 10.12259/j.issn.2095-610X.S20240803
[5]	Jiefu TANG, Dexing YANG, Shengzhe LIU, Qiang WANG, Kai FU, Zhenfang WANG, Ying LUAN, Min LI, Rong LIU. A Study on Prognostic Value of Cellular Immunological Indicators in Omicron Variant Infected Elderly Severe Patients. Journal of Kunming Medical University, 2023, 44(12): 87-94. doi: 10.12259/j.issn.2095-610X.S20231214
[6]	Li CAI, Huaying YANG, Jianhong CHENG, Jia CAO, Na WEI. Changes of Serum Levels of 6-Keto-PGF1α，TGF-α and TXB2 during the Treatment of Peptic Ulcer in Children and Their Influence on Prognosis. Journal of Kunming Medical University, 2023, 44(9): 136-142. doi: 10.12259/j.issn.2095-610X.S20230928
[7]	Ting GAO, Sheng HUANG, Rong GUO, Dedian CHEN. Clinicopathological Features and Prognosis of Mucinous Breast Carcinoma. Journal of Kunming Medical University, 2023, 44(3): 54-60. doi: 10.12259/j.issn.2095-610X.S20230306
[8]	Bangqing LIU, Jianfeng LI, Xiaohui LIU, Jinnan ZHANG, Jinping LIANG. MiR-196b Promotes Proliferation and Migration of Lung Adenocarcinoma by Targeting ERG. Journal of Kunming Medical University, 2023, 44(10): 83-91. doi: 10.12259/j.issn.2095-610X.S20231023
[9]	Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province. Journal of Kunming Medical University, 2022, 43(2): 60-66. doi: 10.12259/j.issn.2095-610X.S20220215
[10]	Zhengqin GENG, Lin XIE, Hongli SONG, Rong LI, Yedan LIAO, Xueqi ZhANG, Jiadai TANG. Clinical Features and Related Prognostic Factors of 88 Cases of Duodenal Adenocarcinoma. Journal of Kunming Medical University, 2022, 43(1): 53-58. doi: 10.12259/j.issn.2095-610X.S20220109
[11]	Honglan CHEN, Yi WU, Tao HU, Yuming WANG. Potential Value of G6PD Activity Detection in the Peripheral Blood for the Diagnosis and Prognosis of Cervical Cancer Patients with High Risk Human Papillomavirus Infection. Journal of Kunming Medical University, 2022, 43(2): 89-95. doi: 10.12259/j.issn.2095-610X.S20220203
[12]	Changmeng HU, Lin WU. Correlation Between Silva Type and Prognosis of Cervical HPV-associated Adenocarcinoma. Journal of Kunming Medical University, 2022, 43(8): 113-121. doi: 10.12259/j.issn.2095-610X.S20220817
[13]	Huajun ZHAO, Guoqing PAN, Ying TANG, Zhiyuan WANG, Xiaowei ZHAO, Xiaoyu TUO. Expressions of ROR1 in Lung Adenocarcinoma and Its Relationship with Spread Through Air Apace. Journal of Kunming Medical University, 2022, 43(11): 22-29. doi: 10.12259/j.issn.2095-610X.S20221128
[14]	Hong-min DUAN, Nan CHEN, Yong-yan YANG, Yun-xia LI, Jin-xiang FENG, Hang LI, Xiu-wen HUANG, Dong-jin LV, Ming ZHANG, Yu-tao ZHAO. Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549. Journal of Kunming Medical University, 2021, 42(8): 40-46. doi: 10.12259/j.issn.2095-610X.S20210808
[15]	Yan-fen MA, Jian HU, Ning ZHANG, Qian WU, Xiao-qin WANG. Changes and Abnormal Patterns of Coagulation Indicators in Patients with Lung Adenocarcinoma and Tuberculosis Pleural Effusion. Journal of Kunming Medical University, 2021, 42(10): 145-150. doi: 10.12259/j.issn.2095-610X.S20211021
[16]	Ma Guo Yu , Xiong Qing , Jiang Guo Qing , Yang Jia Tian , Mu Yun Zhen . . Journal of Kunming Medical University, 2020, 41(07): 30-37.
[17]	Wu Qi Yan , Bian Ge Yuan , Cheng Hui Jun, Li Jiao Xia , Wang Shu Ting , Huang Zhao Lue . . Journal of Kunming Medical University, 2020, 41(09): 32-37.
[18]	Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis. Journal of Kunming Medical University, 2018, 39(08): 47-50.
[19]	Wang Hua . . Journal of Kunming Medical University,
[20]	Xu Jian Xin . . Journal of Kunming Medical University,